SEATTLE, Nov. 12, 2012 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC), a company focused on translating science into novel cancer therapies, announced today the appointment of Monique Greer as Senior Vice President, Corporate Communications and Investor Relations. Ms. Greer will be responsible for leading CTI's external and internal communications strategies and will report directly to James A. Bianco, M.D., President and Chief Executive Officer.
"Monique is a key hire to drive consistent communications globally, as we transition from a product development organization to a commercial organization," said James Bianco. "She has an excellent reputation in the biotechnology industry for developing and executing strategic, results-driven communications programs that advance business objectives. We believe Monique's recent hematology/oncology commercial experience, management discipline and entrepreneurial drive will serve CTI well as we execute on our global strategy to deliver results for both patients and shareholders."
Ms. Greer has more than 17 years' experience planning and implementing strategic biotech/healthcare corporate communications, investor and media relations, and advocacy relations programs in support of product development, commercialization and strategic initiatives. Most recently, Ms. Greer was Vice President of Corporate Communications and Investor Relations for Allos Therapeutics, Inc. (recently acquired by Spectrum Pharmaceuticals). Ms. Greer served previously as Senior Associate in the Corporate Communications and Investor Relations practice for WCG, a global communications agency, where she created and implemented integrated, strategic communications programs for the firm's clients in the United States and Europe. She has also served as Senior Director, Corporate Communications and Investor Relations for Dendreon Corporation, as well as Director, Corporate Communications for Heska Corporation. Ms. Greer received a bachelor of science in Business Administration from Northeastern University.
About Cell Therapeutics, Inc.Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.CellTherapeutics.com.Sign up for email alerts and get RSS feeds at our Web site, http://www.CellTherapeutics.com/investors_alert Contact: Ed BellT: 206.282.7100F: 206.272.4434E: firstname.lastname@example.org www.CellTherapeutics.com/investors SOURCE Cell Therapeutics, Inc.